Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
1.
Gynecol Oncol ; 163(2): 312-319, 2021 11.
Artículo en Inglés | MEDLINE | ID: mdl-34563366

RESUMEN

OBJECTIVE: Immuno-oncology (IO) has rapidly evolved, with many IO therapies either approved or under investigation for multiple malignancies. Biomarkers exist that can predict response to IO therapies including PD-L1 expression, microsatellite instability (MSI), and total mutation burden (TMB). This paper serves to analyze the presence of these biomarkers across gynecologic cancers. METHODS: A total of 16,300 gynecologic cancer specimens submitted for molecular profiling to Caris Life Sciences were reviewed. Immunohistochemistry was performed using the SP142 anti-PD-L1 clone and assessed for intensity. Next-generation sequencing, immunohistochemistry, and fragment analysis were used to determine MSI status. TMB was measured by counting all non-synonymous missense mutations found per tumor not previously described as germline alterations. Chi-Square, Fisher Exact, and the Kruskal-Wallis test were used to compare cohorts. RESULTS: Of 16,300 specimens, 54.1% were ovarian, 37.2% uterine, 7.2% cervical, 0.3% vulvar, 1.2% vaginal, with 0.1% unspecified. MSI-H was most frequent in uterine cancer (17.7%) and only 1% of ovarian cancers. PD-L1 expression was present in 38.3% of cervical and 62.5% of vulvar cancers, but less than 8% of ovarian and uterine cancers. TMB-H was present in 21.1% cervical, 19.7% uterine, and 5% ovarian cancers. Few specimens exhibited a "triple positive" phenotype - 0.3% ovarian, 1.5% uterine, and 1.5% cervical. Associations were seen between MSI, TMB, and PD-L1 across all cancer types. CONCLUSIONS: The frequency of individual biomarkers pertinent to IO therapy varies by cancer type. HPV-driven genital tract cancers have higher frequencies of PD-L1 expression, MSI-H, and TMBH. Endometrial cancers are characterized by MSI-H and TMB, whereas ovarian cancers have a low frequency of MSI-H and modest PD-L1 or TMBH. The incidence of 'triple positive" cases was less than 2%.


Asunto(s)
Biomarcadores de Tumor/genética , Neoplasias de los Genitales Femeninos/genética , Inhibidores de Puntos de Control Inmunológico/uso terapéutico , Inestabilidad de Microsatélites , Antígeno B7-H1 , Toma de Decisiones Clínicas/métodos , Resistencia a Antineoplásicos/genética , Femenino , Neoplasias de los Genitales Femeninos/tratamiento farmacológico , Neoplasias de los Genitales Femeninos/patología , Humanos , Inhibidores de Puntos de Control Inmunológico/farmacología , Mutación , Selección de Paciente
3.
Gynecol Oncol ; 128(2): 316-21, 2013 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-23138135

RESUMEN

OBJECTIVE: Uterine serous carcinoma (USC) constitutes 10% of uterine cancers but ~40% of deaths. Tumor size is a known prognostic factor in other solid tumors. In endometriod cancers it is one element used to identify the need for complete staging, while its significance in USC is debated. Therefore tumor size was examined as an independent prognostic factor. METHODS: Clinical and pathologic variables were recorded for 236 institutional patients, and those patients in the SEER database with USC. Chi-square and Fisher exact t-tests were utilized and survival data generated via Kaplan-Meier method; multivariate analysis was performed via cox-regression. RESULTS: The patients' mean age was 67.2 years (range 40-91). Survival ranged from 0 to 184 months (mean 42.8). We used a tumor size cut-off of 1cm and noted significant associations with myometrial invasion (p<0.0001), angiolymphatic invasion (p<0.0001), peritoneal washings (p=0.03), stage (p=0.015) and positive lymph nodes (p=0.05). Furthermore, recurrence was associated with larger tumors (p=0.03). In multivariate analysis, extra-uterine disease was the only factor associated with both recurrence and survival. Review of the SEER database noted association of larger tumors with lymph node involvement and a significant survival advantage with tumors <1cm in both univariate and multivariate analysis. CONCLUSIONS: Treatment options for USC are often predicated on the surgical stage and therefore components of the staging are vitally important. The 1cm tumor-size cut-off should be studied prospectively as a prognostic indicator of survival and recurrence in USC and considered for inclusion in USC staging.


Asunto(s)
Cistadenocarcinoma Seroso/patología , Neoplasias Uterinas/patología , Adulto , Anciano , Anciano de 80 o más Años , Cistadenocarcinoma Seroso/cirugía , Femenino , Humanos , Histerectomía , Escisión del Ganglio Linfático , Persona de Mediana Edad , Estadificación de Neoplasias , Pronóstico , Programa de VERF , Neoplasias Uterinas/cirugía
4.
Science ; 166(3901): 99-102, 1969 Oct 03.
Artículo en Inglés | MEDLINE | ID: mdl-17769756

RESUMEN

On 1 August between 10:15 and 12:50 Universal Time, with the Lick Observatory 120-inch (304-cm) telescope and a laser operating at 6943 angstroms, return signals from an optical retro-reflector array placed on the moon by the Apollo 11 astronauts were successfully detected. After the return signal was first detected it continued to appear with the expected time delay for the remainder of the night. The observed range is in excellent agreement with the predicted ephemeris. Transmitting between 7 and 8 joules per pulse, we found that each return signal averaged more than one photoelectron. This is in good agreement with calculations of the expected signal strength.

5.
Melanoma Res ; 12(5): 429-34, 2002 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-12394183

RESUMEN

12-Lipoxygenase (12-LOX), through its metabolite 12( )-hydroxyeicosatetraenoic acid [12( )-HETE], has been demonstrated to play a pivotal role in experimental melanoma invasion and metastasis, and 12-LOX expression may be important in early human melanoma carcinogenesis. We have studied the differences in 12-LOX protein expression during the progression of melanoma from human melanocytic cells to benign and dysplastic naevi to malignant metastatic disease. 12-LOX expression was determined in normal human skin melanocytes and in melanocytes found in compound naevi, dysplastic naevi and melanomas using a platelet-type 12-LOX antibody with a diaminobenzidine immunoperoxidase system detection system and was quantified using the analysis software NIH Image 1.62. Mean cellular pixel densities for 12-LOX staining ( = 50 cells/histological type) were unchanged in compound naevi ( = 0.14) and were increased in dysplastic naevi and melanomas compared with normal skin melanocytes ( = 0.03 and = 0.01, respectively). Similarly, melanomas had higher levels of expression compared with dysplastic naevi ( = 0.03). 12-LOX expression was significantly different between compound naevus and dysplastic naevus melanocytes ( = 0.01). These data suggest that 12-LOX may be an important novel marker for cancer progression within the melanoma system, and therefore could be a useful biomarker and therapeutic target for melanoma chemoprevention.


Asunto(s)
Araquidonato 12-Lipooxigenasa/biosíntesis , Melanoma/diagnóstico , Melanoma/enzimología , Neoplasias Cutáneas/diagnóstico , Neoplasias Cutáneas/enzimología , Plaquetas/enzimología , Humanos , Procesamiento de Imagen Asistido por Computador , Inmunohistoquímica , Melanocitos/enzimología , Nevo/enzimología , Lesiones Precancerosas
6.
Appl Opt ; 5(9): 1437-9, 1966 Sep 01.
Artículo en Inglés | MEDLINE | ID: mdl-20057568

RESUMEN

A technique is described which yields quantitative photographic determinations of laser beam intensity distributions. Each photograph is self-calibrated, eliminating the effect of variation from one film sample to another, by a technique which is indifferent to the nonlinear response of the emulsion. Study of the beam divergence characteristics of a saturable dye, Q-switched ruby oscillator-amplifier system is presented.

7.
QRB Qual Rev Bull ; 13(2): 56-60, 1987 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-3104859

RESUMEN

In an effort to implement ongoing and continuous monitoring and evaluation of the quality of care in its unusually complex ambulatory care setting, the University of Chicago Hospitals developed a system of clinic-based activity. All 60 of its clinics use the same procedure, involving indicators that address both servicewide and clinic-specific concerns and a single, adaptable tool for data collection and reporting that makes it easier for centralized bodies to review and act on reports. Specific examples show how the system has improved care and encouraged multidisciplinary involvement in the quality assurance effort.


Asunto(s)
Instituciones de Atención Ambulatoria/organización & administración , Control de Formularios y Registros/métodos , Administración de Consultorio/métodos , Garantía de la Calidad de Atención de Salud , Humanos , Registros Médicos
8.
Appl Opt ; 17(13): 1989-90, 1978 Jul 01.
Artículo en Inglés | MEDLINE | ID: mdl-20203712
9.
Appl Opt ; 12(12)1973 Dec 01.
Artículo en Inglés | MEDLINE | ID: mdl-20125858
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA